CITIUS ONCOLOGY, INC. CTOR
is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company's strategy
centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive
advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved
drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $6.4M | $4.9M | $4.2M | — | — |
| SG&A | $8.8M | $8.1M | $5.9M | $138.1K | — |
| Total operating expenses | $23.5M | $20.6M | $12.1M | — | — |
| Operating income | -$23.5M | -$20.6M | -$1.0M | -$138.1K | — |
| Interest expense | $218.0K | — | — | — | — |
| Pre-tax income | -$23.7M | -$20.6M | -$12.1M | — | — |
| Income tax | $1.1M | $576.0K | $576.0K | — | — |
| Net income | -$24.8M | -$21.1M | -$12.7M | $380.8K | — |
| EPS, basic | -0.34 | -0.31 | -0.19 | 0.12 | — |
| EPS, diluted | -0.34 | -0.31 | -0.19 | 0.12 | — |
| Shares, diluted (wtd. avg.) | $73.3M | $68.1M | $67.5M | $1.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $3.9M | $112 | — | — | — |
| Inventory | $22.3M | $8.3M | — | — | — |
| Total current assets | $27.5M | $11.0M | $7.7M | $377.3K | $126.4K |
| Total assets | $100.9M | $84.4M | $47.7M | $68.2M | $126.4K |
| Accounts payable | $13.2M | $3.7M | $1.3M | — | — |
| Total current liabilities | $49.5M | $32.7M | $21.0M | $31.8K | $136.5K |
| Total liabilities | $56.1M | $38.2M | $22.2M | — | — |
| Retained earnings | -$64.0M | -$39.3M | -$18.1M | $345.3K | -$10.1K |
| Total equity | $44.9M | $46.1M | $25.5M | $36.3M | -$10.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.5M | $126.4K | -$601.3K | -$48.0K | — |
| Stock-based compensation | $8.3M | $7.5M | $2.0M | — | — |
| Investing cash flow | -$5.8M | -$5.0M | -$1.3M | -$67.3M | — |
| Financing cash flow | $15.2M | $4.9M | $1.7M | $67.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-125331.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |